Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    TopAbstracts in Hypertension 11/26/2008 - (DGNews)
    Potassium Loss Caused by Thiazides May Explain Higher Risk of Adult Diabetes - (DGNews)
    High Blood Pressure in Doctor's Office May Not Predict Heart Risks - (DGNews)
    TopAbstracts in Hypertension 11/19/2008 - (DGNews)
    Aliskiren Helps Elderly Patients Achieves Blood Pressure Control: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - Hypertension
    • Minimizing Cardiovascular Risk in Patients With Dyslipidemia
    • Beta-Blockers in Hypertension - The Con Discussion
      Vaccination: A New Approach to RAAS Inhibition?
      Beta-Blockers in Hypertension - The Pro Discussion
      Which Anti-RAAS Shall We Use?

      Webcasts/CME archive

       Recent cases - Hypertension
        Aortic Dissection Type I in a Weightlifter with Hypertension: A Case Report
        Transient Left Ventricular Apical Ballooning and Exercise Induced Hypertension During Treadmill Exercise Testing: Is There a Common Hypersympathetic Mechanism?
        Dilation of Renal Artery Stenosis after Administration of Losartan
        Angioedema of the Tongue
        Primary Aldosteronism Caused by a Unilateral Adrenal Adenoma Accompanied by Autonomous Cortisol Secretion

        Cases archive
          




        my personal edition > hypertension > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Calcium Blockers Not Better Than Other Drug Classes

        A DGReview of :"Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial"
        Journal of the American Medical Association (JAMA)

        05/12/2003
        By David Loshak


        Calcium antagonists are about as effective as diuretics and beta-blockers in reducing cardiovascular disease, but they are not better, according to a 3-year study.

        The Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial, which involved 16,602 patients at 661 centres in 15 countries, "did not demonstrate equivalence of a controlled-onset extended-release verapamil-based anti-hypertensive regimen compared with a regimen beginning with a diuretic or beta-blocker", researchers reported.

        Members of the CONVINCE Research group, based at Rush Medical College of Rush University, in Chicago, Illinois, said their conclusion about the relative efficacy of the three drug classes should be seen "in the context of other trials of calcium antagonists".

        They observed that although hypertensive patients were often given calcium antagonists to reduce cardiovascular risk, the benefit compared to other drug classes was still controversial.

        To see if initial therapy with the controlled-onset extended-release calcium antagonist verapamil was equivalent to a physician's choice of the beta-blocker atenolol or the diuretic hydrochlorothiazide in preventing cardiovascular disease, they conducted the double-blind, randomised clinical CONVINCE trial.

        The participants, diagnosed as having hypertension, also had one or more additional risk factors for cardiovascular disease. They were enrolled between September 1996 and December 1998, and were followed up until the end of 2000.

        Initially, 8,241 participants received controlled-onset extended-release verapamil 180 mg. and 8,361 participants received either atenolol 50 mg or hydrochlorothiazide 12.5 mg. Other drugs, such as diuretics, beta-blockers or angiotensin-converting enzyme inhibitors, could be added in specified sequence if needed.

        Systolic blood pressure in verapamil recipients fell by 13.6 mm Hg and diastolic blood pressure by 7.8 mm Hg.

        Systolic blood pressure in the atenolol and hydrochlorothiazide recipients fell by 13.5 mm Hg and diastolic blood pressure by 7.1 mm Hg.

        With verapamil, there were 364 primary cardiovascular disease-related events and with the other two agents there were 365.

        The risks associated with verapamil and the other two agents differed only marginally for both fatal and non-fatal strokes and myocardial infarctions, for cardiovascular disease-related death, for any pre-specified cardiovascular disease-related event and for all-cause mortality.

        Non-stroke haemorrhages occurred significantly more often with verapamil, affecting 118 recipients, compared with 79 recipients of atenolol or hydrochlorothiazide.

        With all three agents, there were more events related to cardiovascular disease between 6.00 AM and noon than at other times.
        JAMA 2003;289:16:2073-2082. "Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send